SULT1A1 (Minoxidil Sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth

BACKGROUND Minoxidil is a widely used over the counter topical treatment for hair loss. The response rate for topical minoxidil is relatively low. Minoxidil is a pro-drug, converted to its active form, minoxidil sulfate, by SULT1A1 enzymes located in the scalp. Recently, a novel topical formula that increases the activity of SULT1A1 in hair follicles was reported. AIMS To evaluate any benefit of applying the SULT1A1 enzyme booster prior to daily 5% minoxidil treatment. METHODS Male androgenic alopecia patients were recruited to a randomized blinded placebo controlled study. Patients were randomized to receive 5% topical minoxidil plus the novel formula or minoxidil plus a sham adjuvant. Patient's hair growth was monitored using global photography over 60 days. RESULTS Twenty-four males with androgenic alopecia (Norwood scale average 4.4, range 2-6) were randomized and completed the trial; 12 in the active arm and 12 in placebo. 75% of the subjects who used the SULT1A1 adjuvant with their daily minoxidil treatments for 60 days regrew hair verses 33% of those using the placebo adjuvant (p=0.023). CONCLUSIONS In a small cohort of androgenetic alopecia men, adding the SULT1A1 adjuvant to their daily minoxidil treatment regimen improved hair regrowth.

[1]  J. Shapiro,et al.  Novel “After Minoxidil” spray improves topical minoxidil compliance and hair style manageability , 2020, Journal of cosmetic dermatology.

[2]  P. Ramos,et al.  Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  J. Shapiro,et al.  Novel topical booster enhances follicular sulfotransferase activity in patients with androgenetic alopecia: a new strategy to improve minoxidil response , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  M. Šitum,et al.  Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent , 2018, Dermatologic therapy.

[5]  Marshall Godwin,et al.  The effectiveness of treatments for androgenetic alopecia: A systematic review and meta‐analysis , 2017, Journal of the American Academy of Dermatology.

[6]  E. Olsen,et al.  A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. , 2007, Journal of the American Academy of Dermatology.

[7]  G. Johnson,et al.  Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. , 1992, The Journal of investigative dermatology.

[8]  A. Buhl,et al.  Minoxidil sulfate is the active metabolite that stimulates hair follicles. , 1990, The Journal of investigative dermatology.

[9]  M. Šitum,et al.  Identification of the sulfotransferase iso-enzyme primarily responsible for the bio-activation of topical minoxidil. , 2019, Journal of biological regulators and homeostatic agents.

[10]  R. Ghadially,et al.  Influence of pH on Skin Stem Cells and Their Differentiation. , 2018, Current problems in dermatology.

[11]  J. Shapiro,et al.  Clinical utility and validity of minoxidil response testing in androgenetic alopecia , 2015, Dermatologic therapy.